The first clinical isolate of Enterococcus faecium with the VanB phenotype in a teaching hospital in Greece  by Papaparaskevas, J. et al.
Concise Communications 763 
The first clinical isolate of Enterococcusfuecium with the VanB phenotype 
in a teaching hospital in Greece 
Clin Minobiol Infect 1999; 5: 763-765 
J ,  PapaparaSkwaS'~2*, J ,  Stganou', A.  I/atopoulos3, G. 7'homopoulos4 and A .  Avlami2 
'Nikolaou Plastira 19, G R  151 21, 2Microbiology Department, 'LAIKON' General Hospital, 
3Department of Hygiene and Epidemiology, University of Athens Medical School, 
41ntensive Care Unit, 'LAIKON General Hospital, Athens, Greece 
*Tel: +301 6128066 Fax: +301 7783949 
E-mail: iosifpQotenet.gr 
Accepted 31 May 1999 
Enterococci present a serious problem in hospitals, 
especially in the USA, where in intensive care and 
transplantation units as many as 15% of the s t r a i n s  are 
resistant to vancomycin. In Europe the situation with 
regard to vancomycin resistance in clinical isolates is 
better, usually with sporadic cases in intensive care and 
hematology units [l-31. On the other hand, entero- 
cocci with various level of vancomycin resistance have 
been found colonizing the feces of healthy individuals 
in different parts of Europe [4,5]. 
In Greece, there have so far been very few reports 
of vancomycin-resistant enterococci (VRE), possibly 
because of the strict policy for vancomycin use that was 
established early enough in most hospitals by the 
infection control committees. We report a case of intra- 
abdominal infection with an Enterococnrs faecium VanB 
isolate in a patient with Prader-Willy syndrome and 
acute pancreatitis. 
A 14-year-old Caucasian boy was admitted to the 
emergency room of our hospital for acute abdominal 
pain 6 h before, dyspnea, high fever and a low con- 
sciousness level. Physical examination revealed fever 
(40.5OC), acute abdominal pain and tenderness in the 
right part of the abdomen, which reflected to the right 
kidney area. Laboratory results showed a leukocyte 
count of 29 600/mm3 (80% neutrophils), hematocrit 
48.2%, glucose 435 mg/dL (normal range 65-125), 
SGOT 760 IU/L (5-45), SGPT 410 IU/L (5-45), 
amylase 240 IU/L (0-220), and lactate dehydrogenase 
(LDH) 960 IU/L (0-450). Blood gases revealed 
metabolic acidosis (PO2 76, pCO2 27.5 and pH 7.45). 
Chest X-ray was normal, and abdominal ultrasound 
scanning, pedormed with great difficulty (due to excess 
weight), showed liquid in the peritoneal cavity. 
The boy had had a known Prader-Wily syndrome 
since birth (mental deficiency, great obesity, increased 
appetite with ability to consume huge quantities of 
food, sexual infantilism and peripheral muscular atony). 
He also had a history of acute pancreatitis episodes. The 
boy was living in Bulgaria and the family had very 
recently moved to Greece as migrants. 
The patient was admitted to the internal medicine 
department but was immediately transferred to the 
intensive care unit (ICU) because of septic shock with 
spasms and acute dyspnea. He was immediately started 
on antimicrobial treatment with amikacin and cehia- 
xone; this was changed to meropenem, fluconazole 
and ornidazole after 5 days, and again to cef'tazidime, 
fluconazole and ornidazole after 6 more days. His 
general condition remained the same, and high fever 
continued. A CT scan was performed with better 
preparation, and this time revealed a cyst in the 
proximity of the pancreatic body, fluid in the peritoneal 
cavity and fluid in the pleural space. Surgery revealed 
an abscess in the proximity of the head and the body of 
the pancreas; ths  was removed and the area was 
cleaned. The antimicrobial treatment was changed to 
co-trimoxazole, piperacillin+ tazobactam and fluco- 
nazole. The cultures h m  the abscess were negative, as 
were a l l  the blood cultures taken so far. 
A s m a l l  improvement in the patient's general 
condition was observed which lasted for 6 days. On  the 
28th hospital day, fever rose again and his general 
condition deteriorated. Treatment was changed again, 
to ciprofloxacin, vancomycin and fluconazole, with no 
results. A culture specimen was taken h m  the drainage 
on the 36th day, and revealed Pseudomonas aeruginosa 
and Enterococnrs spp. The treatment was changed to 
imipenem and fluconazole. Another set of blood 
cultures was negative. 
On  the 40th hospitalization day, the patient was 
reoperated on but died during the surgical procedure 
as a result of oligemic shock. 
The Enterocoms isolate was identified primarily by 
Gram stain, growth in the presence of bile and 6.5% 
NaCl and hydrolysis of esculin. A Kirby-Bauer disk 
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-on test was done, and species identification as 
well as the MIC measurement were performed by the 
PASCO MICAD semi-automatic system for Gram- 
positives (Difco Laboratories, Detroit, Mi, USA). The 
isolate was Entmwms faecium and was resistant to 
ampicillin, ampicillin+sulbactam, chloramphenicol, 
ciprofloxacin, erythromycin, ofloxacin, rifampicin, co- 
trimoxazole, tobramycin and piperac&+tazobactam. 
It had medium resistance to gentamicin (6 mg/L) and 
vancomycin (16 mg/L) and was susceptible to teico- 
planin and to high levels of gentamicin (512 mg/L) and 
streptomycin (1024 mg/L). The stra in  did not produce 
b-lactamase (the test was performed using nitrocefin 
disks; Cefinase, BBL, Becton Dickinson Microbiology 
Systems, Lockeysvdle, MD, USA). 
The PCR assay proposed by Dutka-Mallen et al[6] 
was performed to confirm species identification and 
determine the genotype of the isolate, which had a 
VanB phenotype (lane 4 in Figure 1). For quality control, 
the strains E. faecium BM4147 (lane 2 in Figure l), 
which harbored the vanA gene, and E. fuectllis V583 
(lane 3 in Figure l), with the vanB gene, were used. 
The enterococci have ~turally occurring resistance 
to various antimicrobial agents, including penicillins 
and cephalosporins. They can also develop plasmid- 
and transposon-mediated resistance to agents such 
as erythromycin, tetracycline, chloramphenicol and 
Resistance to vancomycin was first described in 
1988 [S] . Four major types of vancomycin resistance are 
known. Acquired inducible resistance to both vanco- 
mycin and teicoplanin characterizes the VanA type. 
The VanB type has various levels of acquired and 
inducible resistance to vancomycin but not to teico- 
clindamycin. 
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planin. The presence of VanC is an intrinsic property 
of certain strains such as E. gdlinunrm and E. CcLFse&@avus 
and is characterized by low-level resistance to vanco- 
mycin. The V d  type has been very recently described 
and is s t i l l  under investigation [7]. 
Because of the low level of vancomycin resistance 
of the VanB phenotype, it is sometimes difEcult for 
clinical laboratories to detect it, especially those 
which use the Khy-Bauer disk *on method for 
susceptibility testing. This difKculty was also shown by 
Q.C. Scheme, where hospitals pedorming the Kirby- 
Bauer method had dif5culties in recognizing medium 
vancomycin resistance (A. Vatopoulos, personal com- 
munication). It is preferable to use a method of MIC 
measurement such as the Etest or the microdilution 
method, or, even better, to use a screening method of 
growth in brain-heart infusion agar supplemented with 
6 mg/L vancomycin [9]. 
In Greece, up to now, there has been no sigdcant 
vancomycin resistance. In both local and multicenter 
studies [10,11], the frequency of VRE clinical isolates 
was never higher than 1%. with the exception of one 
study [12] fbm northern Greece, which presented a 
rate of 7.6%. This rate changed to 0% 2 years later in 
the same institution [13]. In our hospital, surveillance 
using the WHONET software has never maled,  until 
now, a VRE strain [14], and the isolate under discussion 
was the first one with vancomycin resistance. To our 
knowledge, it is also the first fully characterized VanB 
E. faecium clinical isolate found in Greece. 
The isolate was considered to be a colonizer rather 
than a true pathogen, since it was isolated fhm 
abdominal drainage only. Colonization was possibly the 
result of prolonged antibiotic use, especially vanco- 
mycin, or of VRE spread fhm patient to patient via 
the hands of personnel or various equipment. At the 
time of isolation, there was no screening program for 
V I U  in patient fecal flora in the ICU, so we did not 
have the opportunity to screen the patient after the 
isolation because of his rapid deterioration and death. 
Immediately after isolation of the first VRE, a rectal 
culture surveillance program was started which is 
currently being carried out in all patients of the ICU 
and certain other departments of the hospital. The feces 
or per i red swabs are cultured in bilcesculifiadde 
agar supplemented with 6 mg/L vancomycin [15]. 
Preliminary results of this study show a 33% rate of 
colonization with VRE among examined patients in 
the ICU. This high colonization rate may explain a 
possible patient-to-patient spread of the strain under 
discussion, via the hands of personnel. 
There is onlv one verv recent studv in Greece on ~. ~~~ 
Figure 1 Agarow gel electrophoresis of the VanB PCR 
product. Lane 1 is the negative control. 
fecal carriage; this indicates a rate of VRE carriage (of 
the v a d  genotype) of about 6% [16]. This study was 
Concise Communications 7 6 5  
performed in a primary and secondary healthcare 
center and it possibly indicates the colonization rate of 
the community. 
This first VRE clinical isolate of the VanB pheno- 
type is probably the tip of the vancomycin resistance 
'iceberg' in our hospital. It indlcates a possible need for 
adjustments in the testing of vancomycin resistance 
and in VRE carriage surveillance in all tertiary-care 
institutions, since the transfer of seriously ill patients 
h m  one hospital to another is common practice. 
Clinical laboratories must adopt a sensitivity testing 
method that is able to recognize the VanB phenotype, 
and should also apply a surveillance program for VRE 
based on the agar-screening test. They must also try to 
reinforce the infection control policies, to reduce the 
risk of nosocomial transmission of VRE. 
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The diagnosis of tuberculosis is well known as being a 
slow process, particularly in extrapulmonary cases. In 
these clinical presentations, the Ziehl-Neelsen stain for 
acid-fast bacilli in smears tends to be negative, making 
